Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

We have observed 18 EP applications Beate Binsack has served for within the last five+ years. (We consider all applications which have an EP A1 publication dated after December 16, 2012). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP11711598

FACTOR XII INHIBITORS FOR TREATING INTERSTITIAL LUNG DISEASE

IPC classification:
A61K 38/00, C07K 14/81
Applicant:
Justus Liebig University Giessen (Justus-Liebig-Universität Gießen)
Agent:
Beate Binsack, CSL Behring GmbH
Status:
EXAMINATION IN PROGRESS
EP12153341

Factor XII inhibitors for the treatment of neurological inflammatory disorders

IPC classification:
A61K 38/06, A61K 38/48, A61K 38/55, A61K 38/57, A61K 39/395, A61K 47/48, A61P 25/00, A61P 37/00
Applicant:
Julius-Maximilians-University of Wuerzburg (Universität Würzburg)
Applicant:
University of Münster (Westfälische Wilhelms-Universität Münster)
Applicant:
CSL Behring GmbH
Applicant:
CSL Ltd.
Agent:
Beate Binsack, CSL Behring GmbH
Status:
APPLICATION REFUSED
EP12707782

FACTOR XII INHIBITORS FOR THE ADMINISTRATION WITH MEDICAL PROCEDURES COMPRISING CONTACT WITH ARTIFICIAL SURFACES

IPC classification:
A61K 38/55, A61K 38/57, A61K 39/395, A61P 9/10, C07K 16/36
Applicant:
CSL Behring GmbH
Agent:
Beate Binsack, CSL Behring GmbH
Status:
GRANT OF PATENT INTENDED
EP12707624

FACTOR XII INHIBITORS FOR THE TREATMENT OF SILENT BRAIN ISCHEMIA AND ISCHEMIA OF OTHER ORGANS

IPC classification:
A61K 38/55, A61K 38/57, A61K 39/395, A61K 49/00, A61P 9/10, C07K 16/36, G01N 33/50
Applicant:
CSL Behring GmbH
Applicant:
Massachusetts General Hospital
Agent:
Beate Binsack, CSL Behring GmbH
Status:
PATENT GRANTED
EP12719993

METHODS TO REDUCE ADVERSE EVENTS CAUSED BY PHARMACEUTICAL PREPARATIONS COMPRISING PLASMA DERIVED PROTEINS

IPC classification:
A61K 31/727, A61K 35/16, A61K 38/57, A61P 1/00, A61P 7/02, A61P 9/06, A61P 9/12, A61P 11/08
Applicant:
CSL Behring GmbH
Agent:
Beate Binsack, CSL Behring GmbH
Status:
GRANT OF PATENT INTENDED
EP12808401

USE OF C1-INHIBITOR FOR THE TREATMENT OF SECONDARY EDEMA OF THE CENTRAL NERVOUS SYSTEM

IPC classification:
A61K 38/57, A61P 7/10, A61P 9/10
Applicant:
CSL Behring GmbH
Agent:
Beate Binsack, CSL Behring GmbH
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP13701651

FACTOR XII INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL INFLAMMATORY DISORDERS

IPC classification:
A61K 38/06, A61K 38/48, A61K 38/55, A61K 38/57, A61K 39/395, A61K 47/48, A61P 25/00, A61P 37/00, C07K 14/00
Applicant:
Julius-Maximilians-University of Wuerzburg (Universität Würzburg)
Applicant:
University of Münster (Westfälische Wilhelms-Universität Münster)
Applicant:
CSL Behring GmbH
Applicant:
CSL Ltd.
Agent:
Beate Binsack, CSL Behring GmbH
Status:
EXAMINATION IN PROGRESS
EP11733884

AN ANCESTRAL SERINE PROTEASE COAGULATION CASCADE EXERTS A NOVEL FUNCTION IN EARLY IMMUNE DEFENSE

IPC classification:
A61K 38/45, A61P 31/00
Applicant:
CSL Behring GmbH
Applicant:
Hansa Medical AB
Agent:
Beate Binsack, CSL Behring GmbH
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12761739

COMBINATION THERAPY USING IMMUNOGLOBULIN AND C1-INHIBITOR

IPC classification:
A61K 38/55, A61K 39/395, A61P 9/10
Applicant:
CSL Behring GmbH
Agent:
Beate Binsack, CSL Behring GmbH
Status:
GRANT OF PATENT INTENDED
EP13823892

A METHOD FOR POLISHING ALBUMIN

IPC classification:
A61K 38/38, C07K 1/16, C07K 14/76
Applicant:
CSL Ltd.
Agent:
Beate Binsack, CSL Behring GmbH
Status:
The patent has been granted
EP13777203

A METHOD OF PURIFYING PROTEINS

IPC classification:
C07K 1/14, C07K 1/16, C07K 1/30, C07K 1/36, C07K 14/47, C07K 14/79
Applicant:
CSL Behring AG
Applicant:
CSL Behring LLC
Agent:
Beate Binsack, CSL Behring GmbH
Status:
EXAMINATION IN PROGRESS
EP13851610

RECONSTITUTED HDL FORMULATION

IPC classification:
A61K 38/17, A61P 3/06
Applicant:
CSL Ltd.
Agent:
Beate Binsack, CSL Behring GmbH
Status:
GRANT OF PATENT INTENDED
EP13861334

A METHOD OF PURIFYING THERAPEUTIC PROTEINS

IPC classification:
A61K 38/36, A61K 38/37, C07K 1/18, C07K 1/20, C07K 14/75, C07K 14/755
Applicant:
CSL Behring GmbH
Agent:
Beate Binsack, CSL Behring GmbH
Status:
GRANT OF PATENT INTENDED
EP14707379

THERAPEUTIC AGENT FOR AMNIOTIC FLUID EMBOLISM

IPC classification:
A61K 38/57, A61P 43/00
Applicant:
CSL Behring GmbH
Agent:
Beate Binsack, CSL Behring GmbH
Status:
PATENT GRANTED
EP14708308

TREATMENT AND PREVENTION OF REMOTE ISCHEMIA-REPERFUSION INJURY

IPC classification:
A61K 38/57, A61K 39/395, A61P 7/02
Applicant:
University of Bern (Universität Bern)
Applicant:
CSL Behring GmbH
Agent:
Beate Binsack, CSL Behring GmbH
Status:
EXAMINATION REQUESTED
EP14808213

PROCESS FOR PREPARING APOLIPOPROTEIN A-I (APO A-I)

IPC classification:
A61K 31/685, A61K 31/688, A61K 38/17, A61P 3/06, C07K 1/14, C07K 1/30, C07K 1/34, C07K 1/36, C07K 14/775
Applicant:
CSL Ltd.
Agent:
Beate Binsack, CSL Behring GmbH
Status:
GRANT OF PATENT INTENDED
EP14739078

COMBINATION THERAPY USING A FACTOR XII INHIBITOR AND A C1-INHIBITOR

IPC classification:
A61K 31/4365, A61K 31/519, A61K 31/60, A61K 31/727, A61K 38/57, A61K 39/395, A61K 45/06, A61K 47/48
Applicant:
CSL Behring GmbH
Agent:
Beate Binsack, CSL Behring GmbH
Status:
GRANT OF PATENT INTENDED
EP14833626

CONTAMINANT REMOVAL METHOD

IPC classification:
A61K 38/16, C07K 1/34, C07K 1/36, C07K 14/775
Applicant:
CSL Ltd.
Agent:
Beate Binsack, CSL Behring GmbH
Status:
GRANT OF PATENT INTENDED

Please Sign in to use this feature